Description
Created On: 2020-07-15
Record Count: 3
Primary Industries
- Drugs
- Diagnostic
- Disease
- Therapeutic
- Technical Know How
- Viral Infection
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 211924
The Product shall mean a pharmaceutical product.
The Licensed Know-How shall mean any proprietary information owned by a third party as of the date disclosed to Licensor under Bucast License consisting of technical information, clinical information, including pre-clinical and clinical data available to Licensor regarding the Compounds or the Celgosivir Program, know-how and inventions, patentable and non-patentable, relating to the use, sale or importation of a Bucast Product, other than the Licensed Manufacturing Know-How.
Celgosivir, which has been evaluated in over 500 subjects in human clinical studies to date, is a novel, oral antiviral agent under development for the treatment of chronic Hepatitis C Virus (“HCVâ€) infections.
IPSCIO Record ID: 203459
This agreement also includes Non-Exclusive Cross-Licenses where each Party hereby grants to the other Party a non-exclusive, royalty-free license, without the right to sub-license:
(i) under such Partys interest in Collaboration Know-How for the manufacture or formulation of products other than Products, including 'cocktail' and other Combination Products; and
(ii) under such Partys interest in Collaboration Know-How, solely to conduct research in the HCV Field in the Territory.
The Collaboration Compound shall mean a Nucleoside that satisfies the chemical and technical requirements set forth, and its Related Compounds and which:
(a) is or was synthesized by or for Licensor on or before the Effective Date or during the Research Program Term; or
(b) is a Related Compound to a Collaboration Compound disclosed by Licensor to Licensee pursuant to Identification and Contribution of Collaboration Compounds and which is synthesized by or for Licensee after the Effective Date.
The Collaboration Compound Products shall mean any preparations in final form, bulk form or other form containing as an active pharmaceutical ingredient one or more Selected Compounds.
The HCV Field shall mean the treatment of chronic hepatitis C viral infections in humans.
The Collaboration Compound Products are for sale by prescription, over-the-counter or any other method, including without limitation any Combination Product.
IPSCIO Record ID: 203549
Each Party hereby grants to the other Party a non-exclusive, non-sublicensable (except to Affiliates) license to its Patent Rights and Know-How solely to the extent necessary to permit such other Party to perform its responsibilities relating to the Anadys Compound or Product under the Development Plan during the term of this Agreement.
The licensing and co-development agreement is for the development and potential commercialization of ANA975 and potentially additional Toll-Like Receptor (“TLR7â€) oral prodrugs for chronic hepatitis C virus (“HCVâ€) and hepatitis B virus (“HBVâ€) infections, as well as other potential infectious disease indications.
ANA975, a 5-amino-3-ß -D-ribofuranosyl-3H-thiazolo[4,5-d]pyrimidin-2-one derivative, was synthesized in the search of an oral prodrug of isatoribine, a small molecule toll-like receptor 7 (TLR-7) agonist.
Toll-like receptor 7, also known as TLR7, is a protein that in humans is encoded by the TLR7 gene.
ID field means the treatment, diagnosis or prevention of infectious diseases outside of the Primary Fields.
HBV field means the treatment, diagnosis or prevention of hepatitis B virus (HBV).
HCV field means the treatment, diagnosis or prevention of hepatitis C virus (HCV).
